TBI-1301 developers

Takara Bio is a leading biotechnology company based in Japan that focuses on the development of innovative gene and cell therapies. The company is well-known for its proprietary RetroNectin technology, which is a global standard for enhancing gene transduction in T-cell therapies. Takara Bio's clinical pipeline is headlined by TBI-1301, a TCR-engineered T-cell therapy targeting NY-ESO-1 for the treatment of synovial sarcoma. In addition to its therapeutic programs, the company operates a significant business in life science research reagents and provides comprehensive CDMO services for genomic medicine. Takara Bio maintains a strategic partnership with Otsuka Pharmaceutical for the commercialization of its lead oncology candidates in the Japanese market.